Cargando…

Correction for: ASXL1 promotes adrenocortical carcinoma and is associated with chemoresistance to EDP regimen

Detalles Bibliográficos
Autores principales:	Wang, Liang, Lyu, Yinfeng, Li, Yuqing, Li, Kunping, Wen, Hui, Feng, Chenchen, Li, Ning
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals 2023
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10637814/ https://www.ncbi.nlm.nih.gov/pubmed/37906268 http://dx.doi.org/10.18632/aging.205255

Ejemplares similares

ASXL1 promotes adrenocortical carcinoma and is associated with chemoresistance to EDP regimen
por: Wang, Liang, et al.
Publicado: (2021)

Correction to: PFKFB4 is overexpressed in clear-cell renal cell carcinoma promoting pentose phosphate pathway that mediates Sunitinib resistance
por: Feng, Chenchen, et al.
Publicado: (2021)

Supportive therapies in patients with advanced adrenocortical carcinoma submitted to standard EDP-M regimen
por: Turla, Antonella, et al.
Publicado: (2022)

EDP-M plus sintilimab in the treatment of adrenocortical carcinoma: a case report
por: Zhang, Zhipeng, et al.
Publicado: (2022)

Correction to: BCL2L2 loss renders ‐14q renal cancer dependent on BCL2L1 that mediates resistance to tyrosine kinase inhibitors
por: Lyu, Yinfeng, et al.
Publicado: (2023)

PFKFB4 is overexpressed in clear-cell renal cell carcinoma promoting pentose phosphate pathway that mediates Sunitinib resistance
por: Feng, Chenchen, et al.
Publicado: (2021)

BCL2L2 loss renders ‐14q renal cancer dependent on BCL2L1 that mediates resistance to tyrosine kinase inhibitors
por: Lyu, Yinfeng, et al.
Publicado: (2021)

Development of a Phagocytosis-Dependent Gene Signature to Predict Prognosis and Response to Checkpoint Inhibition in Clear-Cell Renal Cell Carcinoma
por: Li, Kunping, et al.
Publicado: (2022)

Corrigendum: Development of a phagocytosis- dependent gene signature to predict prognosis and response to checkpoint inhibition in clear-cell renal cell carcinoma
por: Li, Kunping, et al.
Publicado: (2023)

Efficacy of the EDP-M Scheme Plus Adjunctive Surgery in the Management of Patients with Advanced Adrenocortical Carcinoma: The Brescia Experience
por: Laganà, Marta, et al.
Publicado: (2020)

EDP auditing : conceptual foundations and practice /
por: Weber, Ron (Ronald)
Publicado: (1988)

EDP auditing : conceptual foundations and practice /
por: Weber, Ron (Ronald)
Publicado: (1982)

Efficacy of Treatment With PARP Inhibitor and Immunotherapy for Aggressive Adrenocortical Carcinomawith Cushing’s Syndrome Refractory to Treatment With EDP Chemotherapy and Mitotane
por: Greb, Alexandra C, et al.
Publicado: (2021)

Up the EDP pyramid : the complete job hunting manual for computer professionals /
por: French, Jack, 1932-
Publicado: (1981)

Correction to: Adrenocortical carcinoma complicated by renal thrombotic microangiopathy, a case-series
por: de Nattes, Tristan, et al.
Publicado: (2020)

Association between copy-number alteration of +20q, −14q and −18p and cross-sensitivity to tyrosine kinase inhibitors in clear-cell renal cell carcinoma
por: Wang, Liang, et al.
Publicado: (2020)

Cost accounting in the EDP-supported chemical laboratory
por: Gibitz, H. J.
Publicado: (1983)

SAT-LB064 Mitotane Induces Autophagy: A Mechanism to Promote Chemoresistance in Adrenocortical Carcinoma
por: Tompkins, Kenneth, et al.
Publicado: (2019)

Correction to: Antagonizing miR-455-3p inhibits chemoresistance and aggressiveness in esophageal squamous cell carcinoma
por: Liu, Aibin, et al.
Publicado: (2021)

Author Correction: Butein promotes ubiquitination-mediated survivin degradation inhibits tumor growth and overcomes chemoresistance
por: Dong, Xin, et al.
Publicado: (2023)

Publisher Correction: Epigenetic changes in myelofibrosis: Distinct methylation changes in the myeloid compartments and in cases with ASXL1 mutations
por: Nielsen, Helene Myrtue, et al.
Publicado: (2018)

EDP-mitotane in children: reassuring evidence of reversible side-effects and neurotoxicity
por: Steenaard, Rebecca V., et al.
Publicado: (2022)

Correction: Tudor staphylococcal nuclease drives chemoresistance of non-small cell lung carcinoma cells by regulating S100A11
por: Zagryazhskaya, Anna, et al.
Publicado: (2016)

Correction: Screening of cancer tissue arrays identifies CXCR4 on adrenocortical carcinoma: correlates with expression and quantification on metastases using (64)Cu-plerixafor PET
por: Weiss, Ido D., et al.
Publicado: (2018)

Correction: HIF-α activation by the prolyl hydroxylase inhibitor roxadustat suppresses chemoresistant glioblastoma growth by inducing ferroptosis
por: Su, Xiaodong, et al.
Publicado: (2023)

Correction: DeltaNp63alpha-Mediated Induction of Epidermal Growth Factor Receptor Promotes Pancreatic Cancer Cell Growth and Chemoresistance
por: Danilov, Alexey V., et al.
Publicado: (2018)

Correction: Sigala et al. A Comprehensive Investigation of Steroidogenic Signaling in Classical and New Experimental Cell Models of Adrenocortical Carcinoma. Cells 2022, 11, 1439
por: Sigala, Sandra, et al.
Publicado: (2023)

Correction: MicroRNA-490-3p inhibits migration and chemoresistance of colorectal cancer cells via targeting TNKS2
por: Li, Jing, et al.
Publicado: (2023)

Correction: Silence of cancer susceptibility candidate 9 inhibits gastric cancer and reverses chemoresistance
por: Shang, Chao, et al.
Publicado: (2022)

Correction: Hypoxia Drives Dihydropyrimidine Dehydrogenase Expression in Macrophages and Confers Chemoresistance in Colorectal Cancer
por: Malier, Marie, et al.
Publicado: (2022)

Loss of Asxl2 leads to myeloid malignancies in mice
por: Li, Jianping, et al.
Publicado: (2017)

β-Catenin-driven adrenocortical carcinoma is characterized with immune exclusion
por: Liu, Shenghua, et al.
Publicado: (2018)

Correction to: HMGA1 stimulates MYH9-dependent ubiquitination of GSK-3β via PI3K/Akt/c-Jun signaling to promote malignant progression and chemoresistance in gliomas
por: Que, Tianshi, et al.
Publicado: (2022)

Combination chemotherapy with epirubicin, docetaxel and cisplatin (EDP) in metastatic or recurrent, unresectable gastric cancer
por: Lee, S-H, et al.
Publicado: (2004)

Correction: Inhibition of the Tcf/beta-catenin complex increases apoptosis and impairs adrenocortical tumor cell proliferation and adrenal steroidogenesis
por: Leal, Letícia F., et al.
Publicado: (2023)

Correction to: Migration and invasion is inhibited by silencing ROR1 and ROR2 in chemoresistant ovarian cancer
por: Henry, C. E., et al.
Publicado: (2022)

ASXL1 mutations in Chinese patients with essential thrombocythemia
por: Nie, Yan-Bo, et al.
Publicado: (2018)

Adrenocortical Carcinoma
por: Berruti, Alfredo, et al.
Publicado: (2021)

Mutant ASXL1 cooperates with BAP1 to promote myeloid leukaemogenesis
por: Asada, Shuhei, et al.
Publicado: (2018)

ASXL1 plays an important role in erythropoiesis
por: Shi, Hui, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_lic93l51pkqpvodhdc8597p618